US pharmaceutical company Eli Lilly and Co (Lilly) (NYSE:LLY) has signed an agreement with the US government to supply 300,000 vials of its experimental antibody drug to treat COVID-19 for USD375m, Reuters news agency reported on Wednesday.
This agreement is for delivery over the two months following an emergency use authorisation if granted by US regulators. The US government also has the provision to purchase up to an additional 650,000 vials through 30 June 2021, Lilly said.
Reportedly, Lilly had submitted a request to the US Food and Drug Administration in October 2020 for emergency use authorisation of the drug for treating mild to moderate COVID-19 patients.
Lilly added that the US government has committed that patients will have no out-of-pocket costs for the medicine, although healthcare facilities may charge a fee for the product's administration.
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation
Biocytogen partner NEOK Bio secures FDA IND clearance for cancer therapy candidate
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant